ENTITY
Pharmaron Beijing

Pharmaron Beijing (3759 HK)

186
Analysis
Health CareChina
Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.
more
06 Sep 2021 22:26

Novotech Health IPO: A Solid Start to 2021

We examine the PHIP which discloses the 1Q21 results along with additional disclosures and recent developments. Overall, we continue to maintain...

Logo
449 Views
Share
04 Sep 2021 22:37

Novotech Health IPO Initiation: On-Demand Science

Novotech is set to pre-market an HKEx IPO to raise up to $1.5 bn. Novotech’s fundamentals are solid and the IPO is worth a look for investors...

Logo
417 Views
Share
31 Aug 2021 05:15

EM Fund Positioning:  All You Need to Know

In this analysis, we provide a detailed overview of investor positioning among 250 active Global Emerging Market funds with combined AUM of $500bn.

Logo
433 Views
Share
12 Aug 2021 09:23

Pre-IPO Ambio Pharmaceuticals - The Particularity of Peptide Drugs, the Strength and the Concerns

The article mainly analyzed Ambio Pharmaceuticals in terms of the particularity of peptide drugs & industry characteristics, the strength of its...

Logo
633 Views
Share
11 Aug 2021 09:00

Pre-IPO Asymchem Laboratories - The Strength and the Concerns

The article mainly analyzed Asymchem Laboratories in terms of the industry characteristics, the strength of its business, the comparison with...

Logo
427 Views
Share
x